Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.

The journal of pathology. Clinical research - 1 Jul 2018

Khalique Saira, Naidoo Kalnisha, Attygalle Ayoma D, Kriplani Divya, Daley Frances, Lowe Anne, Campbell James, Jones Thomas, Hubank Michael, Fenwick Kerry, Matthews Nicholas, Rust Alistair G, Lord Christopher J, Banerjee Susana, Natrajan Rachael

Abstract excerpt

ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ARID1A defects. However, the accuracy of ARID1A immunohistochemistry (IHC) as a surrogate for mutation status has not fully been established for patient stratification in clinical trials. Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Endometrioid

Share to DNA-Binding Proteins

Share to Genital Neoplasms, Female

Share to Immunohistochemistry

Share to Nuclear Proteins

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29659191
DOI: 10.1002/cjp2.103
PMCID: PMC6065117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.PMID 29659191Read ↗

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.Semantic proximity Read ↗

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian CarcinomaSemantic proximity Read ↗

Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers‡.Semantic proximity Read ↗

ARID1A gene mutation in ovarian and endometrial cancers (Review).Semantic proximity Read ↗

Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.Semantic proximity Read ↗

ARID1A mutations in endometriosis-associated ovarian carcinomas.Semantic proximity Read ↗

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

Translational genomics of ovarian clear cell carcinoma.Semantic proximity Read ↗

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.Semantic proximity Read ↗

Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.Semantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

Deciphering the Pleiotropic Role of ARID1a and RIF1 in Endometrioid Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.